Extragonadal germ cell tumors.Clinicopathologic findings and treatment experience in 12 patients
| Autor: | David G. McLeod, Steven J. Skoog, H. Grant Taylor, Robert D. Knight, Nancy A. Dawson, Jeffrey A. Waxman |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
Cancer Research
Vincristine medicine.medical_specialty Pathology Chemotherapy Extragonadal business.industry medicine.medical_treatment Combination chemotherapy medicine.disease Debulking Gastroenterology Human chorionic gonadotropin Oncology Internal medicine medicine Germ cell tumors business Progressive disease medicine.drug |
| Zdroj: | Cancer. 61:1187-1191 |
| ISSN: | 1097-0142 0008-543X |
| DOI: | 10.1002/1097-0142(19880315)61:6<1187::aid-cncr2820610622>3.0.co;2-8 |
| Popis: | In patients with primary germ cell tumors, treatment with combination chemotherapy followed by surgical debulking of residual tissue usually produces favorable results. The best treatment for patients with extragonadal germ cell tumors (EGCT) remains a problem. In our series of 12 patients, important clinical features were related to the site of bulky tumor, and all patients exhibited sharply elevated levels of lactate dehydrogenase (LDH), beta subunit human chorionic gonadotropin (beta-HCG), and/or alpha-fetoprotein (AFP). Each patient was treated with systemic chemotherapy, and ten were treated with the same combination chemotherapy--cyclophosphamide, actinomycin, vinblastine, bleomycin, and cisplatin (VAB) alternating with VP-16 and vincristine (VV). Of these ten patients, five died of progressive disease, three of whom had brain metastases. The other five are alive and clinically free of disease. The addition of VP-16 and vincristine did not improve responses. Advanced disease at presentation contributes to the poorer prognosis for these patients. Earlier diagnosis and surgical debulking may improve the long-term survival of patients with this disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text